In lung cancer cell lines with either wild-type or mutant EGFR, treatment with erlotinib and gefitinib induced autophagy, and the degree of induction was greater in resistant cells, suggesting that autophagy is involved in both innate and acquired resistance to EGFR-target therapy55–58. Here, EGFR is linked to lung carcinoma.